Is Sight Sciences, Inc. (SGHT) a Buy, Sell, or Hold?
NASDAQ : SGHT
Sight Sciences, Inc.
$7.09 USD
$1.54 (27.75%)
- Volume
- 776.56K
- Average Volume
- 190.62K
- Market Capitalization
- $385.77M
- P/E Ratio
- -12.70
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $9.24
- Year Low
- $3.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.95
Company Overview
NASDAQ
Paul Badawi
Medical - Devices
Healthcare
SGHT
186
US
USD
Liquidity Metrics
0.79
4.95
4.67
3.89
0.00
Sales & Valuation
$77.36M
4.63
7.31
-12.68
-0.56
Profitability
-$0.74
-$38.43M
-35.69%
-35.73%
-50.64%
-28.37%
P/E Metrics
-12.70
-0.22
-0.22
Analyst Price Target & Rating
$7.50
$8.00
$7.00
1/5
9 Analysts
-5.47%
Financial Health Scores
-0.94
4/9
$80.94M
$104.87M
$51.98M
-$24.64M
Key Metrics (TTM)
$264.2M
3.17
-10.91
4.95
-50.64%
-29.34%
-10.09%
-10.07%
188 days
Company Executives
| Name | Title |
|---|---|
| Jeremy Hayden | Chief Legal Officer & Corporate Secretary |
| Kelly Petrucci | Senior Vice President of Market Access & Strategy |
| Kelly Vaupel | Vice President of Marketing & Commercial Strategy, Interventional Glaucoma |
| James Rodberg | CFO & Treasurer |
| Paul Badawi | Co-Founder, President, Chief Executive Officer & Director |
| David Badawi | Co-Founder, Chief Technology Officer & Director |
| Brenton Taylor | Executive Vice President of Operations and R&D |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics & Compliance Officer |
| Alison Perry Bauerlein | Chief Operating Officer |
Poll Results
No votes yet today — be the first to share your view!
About Sight Sciences, Inc. (NASDAQ:SGHT) Stock
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, Californ ... ia.
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
2026-08-06 09:54:11
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences Q2 Earnings Call Highlights
2026-08-06 01:04:41
Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Sight Sciences Q2 Earnings Call Highlights
2026-08-06 01:03:51
Sight Sciences (NASDAQ: SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance. Total revenue for the quarter ended June 30 was $23.4
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 19:11:46
Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
2026-08-05 19:01:16
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sight Sciences Reports Second Quarter 2026 Financial Results
2026-08-05 16:05:00
Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
2026-08-05 16:04:00
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients' lives, today announced that Aetna, Inc.'s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences' interventional glaucoma technologies.
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
2026-08-04 17:37:00
New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.
Frequently Asked Questions
-
What is the current Sight Sciences, Inc. (SGHT) stock price?
-
Sight Sciences, Inc.(NASDAQ:SGHT) stock price is $7.09 in the last trading session. During the trading session, SGHT stock reached the peak price of $9.236 while $3.19 was the lowest point it dropped to. The percentage change in SGHT stock occurred in the recent session was 27.75% while the dollar amount for the price change in SGHT stock was $1.54.
-
SGHT's industry and sector of operation?
-
The NASDAQ listed SGHT is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of SGHT?
-
Jeremy Hayden | Chief Legal Officer & Corporate Secretary
Kelly Petrucci | Senior Vice President of Market Access & Strategy
Kelly Vaupel | Vice President of Marketing & Commercial Strategy, Interventional Glaucoma
James Rodberg | CFO & Treasurer
Paul Badawi | Co-Founder, President, Chief Executive Officer & Director -
How many employees does SGHT have?
-
Number of SGHT employees currently stands at 186. SGHT operates from 4040 Campbell Avenue, Menlo Park, CA 94025, US.
-
Link for SGHT official website?
-
Official Website of SGHT is: https://www.sightsciences.com
-
How do I contact SGHT?
-
SGHT could be contacted at phone #877 266 1144 and can also be accessed through its website. SGHT operates from 4040 Campbell Avenue, Menlo Park, CA 94025, US.
-
How many shares of SGHT are traded daily?
-
The average number of SGHT shares traded daily for last 3 months was 190.62K.
-
What is the market cap of SGHT currently?
-
The market value of SGHT currently stands at $385.77M with its latest stock price at $7.09